Workflow
奥赛康(002755) - 2023 Q3 - 季度财报
ASK PHARMASK PHARM(SZ:002755)2023-10-30 16:00

Financial Performance - The net profit for Q3 2023 was -219,963,187.35 CNY, a decrease of 129.46% compared to -95,859,950.66 CNY in the same period last year[8] - Total operating revenue for the current period was ¥1,119,748,100.35, a decrease of 25.7% compared to ¥1,506,190,272.21 in the previous period[18] - Net loss for the current period was ¥219,963,187.35, compared to a net loss of ¥95,859,950.66 in the previous period, indicating a significant increase in losses[21] - Basic and diluted earnings per share for the current period were both -0.20, compared to -0.07 in the previous period[23] - Net profit attributable to shareholders is -¥26,203,305.57, an increase of 67.55% year-over-year[37] - Net profit after deducting non-recurring gains and losses is -¥40,392,934.16, a decrease of 55.96% compared to the previous year[37] - Cumulative net profit from the beginning of the year to the reporting period is -¥184,655,635.86, a decrease of 170.58% compared to the same period last year[37] Cash Flow - Operating cash flow for Q3 2023 was -9,404,569.09 CNY, down 123.36% from 40,252,389.49 CNY in Q3 2022[8] - Cash inflow from operating activities totaled 1,446,666,613.62 RMB, down 24.5% from 1,915,896,844.89 RMB in the previous period[29] - Cash outflow from operating activities was 1,456,071,182.71 RMB, a decrease of 22.3% compared to 1,875,644,455.40 RMB in the previous period[29] - Cash inflow from financing activities was 220,498,700.00 RMB, up 40.3% from 157,018,000.00 RMB in the previous period[29] - Net cash flow from financing activities increased to 167,186,491.72 RMB, compared to 62,818,814.30 RMB in the previous period[29] - Cash flow from operating activities shows a net outflow of -¥9,404,569.09, a decrease of 123.36% year-over-year[37] Assets and Liabilities - The total assets as of September 30, 2023, amounted to 3,443,082,484.66 CNY, compared to 3,414,367,396.12 CNY at the end of the previous year[14] - The total liabilities increased to ¥598,777,570.21 from ¥401,028,107.04, reflecting a rise of 49.2%[18] - Total equity attributable to shareholders of the parent company decreased to ¥2,801,580,742.63 from ¥2,962,969,644.26, a decline of 5.4%[18] - Total assets at the end of the reporting period are ¥3,443,082,484.66, an increase of 0.84% from the end of the previous year[37] - Shareholders' equity attributable to the parent company is ¥2,801,580,742.63, a decrease of 5.45% compared to the previous year[37] Investment Activities - The company reported a 61.30% increase in prepayments, totaling 15,232,625.26 CNY, primarily due to advances for materials and R&D expenditures[8] - The company’s other equity instrument investments increased by 267.05%, reaching 13,987,632.46 CNY, attributed to new minority equity investments[8] - Cash inflow from investment activities amounted to 2,607,205,258.17 RMB, an increase of 5.0% from 2,482,392,813.28 RMB in the previous period[29] - The company received 2,588,000,000.00 RMB from investment recoveries, an increase from 2,482,000,000.00 RMB in the previous period[29] Other Comprehensive Income - Other comprehensive income after tax for the current period was ¥14,058,092.57, slightly up from ¥13,402,542.91 in the prior period[21] - The company experienced a decrease in investment income to ¥22,227,327.77 from ¥23,125,015.03, a decline of 3.9%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,174[9] - The company’s cash and cash equivalents increased to 822,594,495.77 CNY from 772,714,279.67 CNY at the beginning of the year[14] - The ending balance of cash and cash equivalents was 814,241,824.54 RMB, slightly down from 833,144,628.84 RMB in the previous period[29] - The company reported a net increase in cash and cash equivalents of 53,565,585.10 RMB, contrasting with a decrease of 327,753,229.67 RMB in the previous period[29]